GSK Sells Last Haleon Shares for $1.58 Billion
By Ian Walker
GSK said has sold its remaining stake in Haleon for GBP1.25 billion ($1.58 billion), ending its gradual disposal of shares in the company formed by a joint venture with Pfizer in 2019.
The British pharmaceutical company said Friday that it has sold 385.3 million shares in Haleon at 324 pence each as flagged late Thursday. The shares were sold via an accelerated bookbuild and the price is a 2.5% discount to Haleon's closing price of 332.40 pence on Thursday.
GSK has drawn down its stake in Haleon since last May, while U.S. pharmaceutical giant Pfizer reduced its holdings to 22.6% from 32% in March. Haleon was formed in July 2019 from the merger of GSK and Pfizer's consumer-healthcare businesses before being spun off and listed on the London Stock Exchange in July 2022.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
May 17, 2024 02:24 ET (06:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase